The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
=== Health care === In 2019, Pritzker approved a tax on private insurance to help fund the state's Medicaid program. In August of that year, he signed legislation to eliminate the state's backlog of Medicaid applications, which as of March 15, 2019, included 112,000 that remained unprocessed past the federal 45-day limit. According to data from the Illinois Department of Human Services, the backlog was eliminated as of June 2020. In August 2023, under provisions of Illinois House Bill 2189 (the Access to Afford Insulin Act), Pritzker signed legislation capping insurance holders' out-of-pocket price of insulin at $35 for a 30-day supply. In July 2024, Pritzker signed bills allowing Illinois to spend $10 million to purchase medical debt from creditors, known as the Medical Debt Relief Pilot Program, under the Illinois Department of Healthcare and Family Services. The program was created to eliminate nearly $1 billion in medical debt for 340,000 low-income state residents. In February 2025, Pritzker announced that approximately 270,000 Illinoisans' medical debt, totaling $345 million, had been erased under the program. On April 22, 2025, United States Secretary of Health and Human Services Robert F. Kennedy Jr. announced a plan to use government data to help determine the causes of autism. In response, Pritzker signed an executive order that made Illinois the first state to block the federal government from collecting personal health data related to autism. In 2025, Pritzker signed Illinois House Bill 1697, the Prescription Drug Affordability Act.
It is assumed that the transection of white substance of the frontal lobes impairs their connection with the thalamus and eliminates the possibility of receiving from it stimuli which lead to irritation and, on the whole, derange mental functions. This explanation is mechanistic and goes back to the narrow localizationism characteristic of American psychiatrists, from where leucotomy was imported to us. The Soviet Union officially banned the procedure in 1950 on the initiative of Gilyarovsky. Doctors in the Soviet Union concluded that the procedure was "contrary to the principles of humanity" and "'through lobotomy' an insane person is changed into an idiot". By the 1970s, numerous countries had banned the procedure, as had several US states. In 1977 after the National Research Act created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, the Commission investigated allegations that psychosurgery – including lobotomy techniques – were used to control minorities and restrain individual rights. Its published report did not recommend a ban on psychosurgery, but noted that the risks to patients from psychosurgery and its potential abuse required strong safeguards. Torsten Wiesel has called the award of the Nobel Prize to Moniz an "astounding [error] of judgment ... a terrible mistake", and there have been calls for the Nobel Foundation to rescind the award.
As for plants, the country has between 40,000 and 45,000 plant species, equivalent to 10 or 20% of total global species, which is even more remarkable given that Colombia is considered a country of intermediate size. Colombia is the second most biodiverse country in the world, lagging only after Brazil which is approximately 7 times bigger. Colombia has about 2,000 species of marine fish and is the second most diverse country in freshwater fish. It is also the country with the most endemic species of butterflies, is first in orchid species, and has approximately 7,000 species of beetles. Colombia is second in the number of amphibian species and is the third most diverse country in reptiles and palms. There are about 1,900 species of mollusks and according to estimates there are about 300,000 species of invertebrates in the country. In Colombia there are 32 terrestrial biomes and 314 types of ecosystems. Protected areas and the "National Park System" cover an area of about 14,268,224 hectares (142,682.24 km2) and account for 12.77% of the Colombian territory. Compared to neighboring countries, rates of deforestation in Colombia are still relatively low. Colombia had a 2018 Forest Landscape Integrity Index mean score of 8.26/10, ranking it 25th globally out of 172 countries. Colombia is the sixth country in the world by magnitude of total renewable freshwater supply, and still has large reserves of freshwater.
DHA (dihydroxyacetone, also known as glycerone) is not a dye, stain or paint, but causes a chemical reaction with the amino acids in the dead layer on the skin surface. One of the pathways is a free radical-mediated Maillard reaction. The other pathway is the conventional Maillard reaction, a process well known to food chemists that causes the browning that occurs during food manufacturing and storage. It does not involve the underlying skin pigmentation nor does it require exposure to ultraviolet light to initiate the color change. However, for the 24 hours after self-tanner is applied, the skin is especially susceptible to ultraviolet, according to a 2007 study led by Katinka Jung of the Gematria Test Lab in Berlin. Forty minutes after the researchers treated skin samples with high levels of DHA they found that more than 180 percent additional free radicals formed during sun exposure compared with untreated skin. Another self-tanner ingredient, erythrulose, produced a similar response at high levels. For a day after self-tanner application, excessive sun exposure should be avoided and sunscreen should be worn outdoors, they say; an antioxidant cream could also minimize free radical production. Although some self-tanners contain sunscreen, its effect will not last long after application, and a fake tan itself will not protect the skin from UV exposure. The study by Jung et al. further confirms earlier results demonstrating that dihydroxyacetone in combination with dimethylisosorbide enhances the process of (sun-based) tanning.
Sources: en.wikipedia.org
Appearing to meet the concern, in Überseering BV v Nordic Construction GmbH the Court of Justice held that a German court could not deny a Dutch building company the right to enforce a contract in Germany, simply because it was not validly incorporated in Germany. Restrictions on freedom of establishment could be justified by creditor protection, labour rights to participate in work, or the public interest in collecting taxes. But in this case denial of capacity went too far: it was an "outright negation" of the right of establishment. Setting a further limit, in Cartesio Oktató és Szolgáltató bt the Court of Justice held that because corporations are created by law, they must be subject to any rules for formation that a state of incorporation wishes to impose. This meant the Hungarian authorities could prevent a company from shifting its central administration to Italy, while it still operated and was incorporated in Hungary. Thus, the court draws a distinction between the right of establishment for foreign companies (where restrictions must be justified), and the right of the state to determine conditions for companies incorporated in its territory, although it is not entirely clear why.
An X-ray examination can be used to detect changes in the size, density and position of the kidneys as well as some urinary stones (struvite and calcium oxalate stones are "radiopaque") and soft tissue calcifications. In severely emaciated cats or fluid accumulations in the retroperitoneal space, however, the kidney can only be visualized to a limited extent on the X-ray image due to the resulting reduction in contrast. Excretory urography, in which a radiopaque contrast medium (e.g. Iopamidol, Iohexol) is injected into the bloodstream and its excretion via the kidneys is recorded radiographically. This makes it possible to detect circulatory disorders, dysfunctions of the renal corpuscles and obstructions of the outflow pathways.
The "Cave of the Seafarers" (Höhle der Seereise) is dated by Rhies to the early 5th century CE, based on stylistic analysis. Carbon dates are significantly later, circa 561-637 CE. The cave contained long narrative sequences about various paths to enlightenment. Most of the panels are now in the Dahlem Museum. The content of the paintings in the "Cave of the Seafarers" is clearly derived from Gandharan prototypes. A painter "Rumakama" (, "the one from Rome"), appears in a Sanskrit inscription in the cave. The inscription, scribbled on the right side of the mural, reads:
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.